5-Methyl-3-nitro-1H-pyrazole - CAS 1048925-02-5
Catalog: |
BB059416 |
Product Name: |
5-Methyl-3-nitro-1H-pyrazole |
CAS: |
1048925-02-5 |
Synonyms: |
5-methyl-3-nitro-1h-pyrazole; 3-Methyl-5-nitro-1H-pyrazole; 5-methyl-3-nitropyrazole; 3-Methyl-5-nitropyrazole; 3-nitro-5-methylpyrazole |
IUPAC Name: | 3-methyl-5-nitro-1H-pyrazole |
Description: | 5-Methyl-3-nitro-1H-pyrazole is a reagent used in the preparation of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase. |
Molecular Weight: | 127.1 |
Molecular Formula: | C4H5N3O2 |
Canonical SMILES: | CC1=NNC(=C1)[N+](=O)[O-] |
InChI: | InChI=1S/C4H5N3O2/c1-3-2-4(6-5-3)7(8)9/h2H,1H3,(H,5,6) |
InChI Key: | ASURMMBYYOJOTQ-UHFFFAOYSA-N |
References: | Trani, G., et al. Bioorg. Med. Chem. Lett., 24, 5818 (2014). |
GHS Hazard Statement: | H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
CN-112574213-A | Synthesis method of pyrazolotriazine energetic compound | 20201211 |
CA-3115000-A1 | Indolinone compounds for use as map4k1 inhibitors | 20181005 |
CN-113227049-A | Indolinone compounds as MAP4K1 inhibitors | 20181005 |
KR-20210068479-A | Indolinone Compounds for Use as MAP4K1 Inhibitors | 20181005 |
JP-2022502455-A | Indolinone compounds for use as MAP4K1 inhibitors | 20181005 |
US-2021198210-A1 | Method for preparing nitropyrazoles | 20180831 |
TW-201938566-A | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical composition, therapeutic method and method of manufacturing the same | 20180215 |
US-2019248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | 20180215 |
WO-2019161078-A1 | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them | 20180215 |
AU-2019222758-A1 | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them | 20180215 |
Complexity: | 122 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 127.038176411 |
Formal Charge: | 0 |
Heavy Atom Count: | 9 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 127.038176411 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 74.5Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 0.8 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS